FDA Issues Warning on Improper Use of Glutathione

MANILA: The Food and Drug Administration (FDA) has issued a cautionary statement regarding the use of glutathione, particularly emphasizing its approved application solely for Cisplatin chemotherapy treatment. FDA Attorney III Pamela Angeline Sevilla, in a radio interview, clarified that glutathione products not related to Cisplatin chemotherapy treatment are not approved by the agency. Cisplatin is an anticancer drug used for advanced-stage cancers.

According to Philippines News Agency, The FDA and the Department of Health (DOH) have consistently warned against the non-prescribed use of glutathione, noting a rise in unregulated products sold online. Sevilla pointed out that online sellers might be marketing unregistered glutathione products, bypassing FDA authorization. The agency previously issued a public advisory highlighting the risks associated with injectable lightening agents like glutathione, which can cause liver, kidney, and nervous system damage, and increase the risk of infectious diseases. This warning comes in the wake of a report about a 96-year-old woman’s death following glutathione and stem cell intravenous infusion in Quezon City. Sevilla reiterated the FDA’s commitment to regulating and monitoring the market to ensure public safety.